Long Noncoding RNAs: Clarity or Confusion?
Because They Are Such Elusive Prey, lncRNAs Have Yet to Emerge as Therapeutic Targets
Markets Expand for Single-Use Bioreactors
Biobags Offer Advantages Over Fixed-Tank Systems
The Challenges of Harmonizing Biomarker Data
Why Trial Success Depends on It
Top 10 Wall Street Losers of 2016
These Companies Lost the Most in a Down Year for Biopharma Stocks
For full access to this article login to GEN Select now.
Wide-Ranging Applicability of Biomarkers Transforms Discovery
Early Use Can Mitigate Some Risks and Increase Likelihood of Compound Advancement
- As a builder asks which tools are most beneficial, so do scientists as they work to create compounds to send into the clinic. Finding the protein and pathway targets of interest are only part of the puzzle; the means to find these are only as good as the tools ...
Not registered yet? Please fill out the form below and enjoy complimentary access to this and an exclusive collection of premium content and personalization features as a GEN Select insider. Learn More.
Get GEN Select Access Now
- Do not put any letters or characters here if you are not a spy program.